Comparison of Daclatasvir Resistance Barriers on NS5A from Hepatitis C Virus Genotypes 1 to 6: Implications for Cross-Genotype Activity

Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection

(2014) Mark S. Sulkowski et al.   NEW ENGLAND JOURNAL OF MEDICINE

Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA

(2014) David B. Ascher et al.   Scientific Reports

Persistence of Resistant Variants in Hepatitis C Virus-Infected Patients Treated with the NS5A Replication Complex Inhibitor Daclatasvir

(2013) Chunfu Wang et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Differential Sensitivity of 5′UTR-NS5A Recombinants of Hepatitis C Virus Genotypes 1−6 to Protease and NS5A Inhibitors

(2013) Yi-Ping Li et al.   GASTROENTEROLOGY

Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir

(2013) Fiona McPhee et al.   HEPATOLOGY

A 96-well based analysis of replicon elimination with the HCV NS5A replication complex inhibitor daclatasvir

(2013) Donald R. O’Boyle et al.   JOURNAL OF VIROLOGICAL METHODS

Characterizations of HCV NS5A replication complex inhibitors

(2013) Donald R. O'Boyle II et al.   VIROLOGY

In VitroActivity of Daclatasvir on Hepatitis C Virus Genotype 3 NS5A

(2012) Chunfu Wang et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

MK-5172, a Selective Inhibitor of Hepatitis C Virus NS3/4a Protease with Broad Activity across Genotypes and Resistant Variants

(2012) Vincenzo Summa et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Hepatitis C Virus RNA Elimination and Development of Resistance in Replicon Cells Treated with BMS-790052

(2012) Chunfu Wang et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Combination Treatment with Hepatitis C Virus Protease and NS5A Inhibitors Is Effective against Recombinant Genotype 1a, 2a, and 3a Viruses

(2012) Judith M. Gottwein et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Impact of a baseline polymorphism on the emergence of resistance to the hepatitis C virus nonstructural protein 5a replication complex inhibitor, BMS-790052

(2012) Jin-Hua Sun et al.   HEPATOLOGY

Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial

(2012) Stanislas Pol et al.   LANCET INFECTIOUS DISEASES

Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1

(2012) Anna S. Lok et al.   NEW ENGLAND JOURNAL OF MEDICINE

In VitroActivity of BMS-790052 on Hepatitis C Virus Genotype 4 NS5A

(2011) Chunfu Wang et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1

(2011) Richard E. Nettles et al.   HEPATOLOGY

Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in Humans: In Vitro and In Vivo Correlations

(2011) Robert A. Fridell et al.   HEPATOLOGY

Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders

(2011) Kazuaki Chayama et al.   HEPATOLOGY

Distinct Functions of NS5A in Hepatitis C Virus RNA Replication Uncovered by Studies with the NS5A Inhibitor BMS-790052

(2011) R. A. Fridell et al.   JOURNAL OF VIROLOGY

Small Molecules Targeting Hepatitis C Virus-Encoded NS5A Cause Subcellular Redistribution of Their Target: Insights into Compound Modes of Action

(2011) P. Targett-Adams et al.   JOURNAL OF VIROLOGY

Resistance Analysis of the Hepatitis C Virus NS5A Inhibitor BMS-790052 in an In Vitro Replicon System

(2010) R. A. Fridell et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Recombinant HCV Variants With NS5A From Genotypes 1–7 Have Different Sensitivities to an NS5A Inhibitor but Not Interferon-α

(2010) Troels K.H. Scheel et al.   GASTROENTEROLOGY

A perspective on modelling hepatitis C virus infection

(2010) J. Guedj et al.   JOURNAL OF VIRAL HEPATITIS

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

(2010) Min Gao et al.   NATURE

Identification of Hepatitis C Virus NS5A Inhibitors

(2009) J. A. Lemm et al.   JOURNAL OF VIROLOGY

Effect of Ribavirin on the Mutation Rate and Spectrum of Hepatitis C Virus In Vivo

(2009) J. M. Cuevas et al.   JOURNAL OF VIROLOGY